Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.
Summary
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).
Official title: A Multicenter, Open-label Phase II/III Clinical Trial of VRT106 in Combination With Camrelizumab and Apatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Immune Checkpoint Inhibitor Therapy
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2026-05-13
Completion Date
2029-06-30
Last Updated
2026-05-15
Healthy Volunteers
No
Conditions
Interventions
VRT106
VRT106,Intravenous infusion
VRT106 in combination with camrelizumab and apatinib
VRT106: Intravenous infusion Camrelizumab: Intravenous infusion Apatinib: Oral administration
Investigator's Choice of Standard of Care
At the investigator's discretion
Locations (1)
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China